Flecainide for supraventricular tachycardia in children

Area of Science:

• Cardiology
• Pediatric Electrophysiology
• Pharmacology

Background:

• Supraventricular tachycardia (SVT) is a common arrhythmia in pediatric and young adult patients.
• Previous antiarrhythmic therapies were often ineffective in patients with SVT.
• Flecainide's role in pediatric SVT management required further investigation.

Purpose of the Study:

• To evaluate the clinical efficacy of flecainide in treating pediatric and young adult patients with SVT.
• To assess the adverse effects and pharmacokinetics of flecainide in this population.
• To determine the effectiveness of flecainide across different mechanisms of SVT.

Main Methods:

• A cohort of 16 pediatric and young adult patients with diagnosed SVT were enrolled.
• Intracardiac electrophysiologic studies were used to determine arrhythmia mechanisms.
• Patients were treated with flecainide, with dosage adjustments based on response and tolerance.

Main Results:

• Flecainide successfully controlled SVT in 8 out of 16 patients (50%).
• Efficacy varied by arrhythmia mechanism: successful control in 3/7 accessory connection, 3/4 AV node reentry, 1/2 atrial automatic focus, and 1/3 atrial flutter.
• No significant adverse effects, including congestive heart failure or proarrhythmic events, were observed.

Conclusions:

• Flecainide demonstrates clinical efficacy in controlling SVT in a significant portion of pediatric and young adult patients.
• The drug is generally well-tolerated with a low incidence of adverse effects and proarrhythmic events.
• Flecainide represents a viable treatment option for specific types of SVT in younger populations.